ResMed Inc is a global leader in digital health and cloud-connected devices that serve individuals with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions. The company specializes in creating innovative solutions that improve the quality of life for patients through advanced technology, including ventilators, sleep therapy devices, and patient monitoring systems. By leveraging data analytics and machine learning, ResMed enhances patient engagement and treatment adherence, thereby promoting better health outcomes. The company's commitment to research and development allows it to continuously advance its portfolio, making a significant impact on the healthcare landscape. Read More
RESMED INC (NYSE:RMD) is a high-quality stock with strong revenue growth, exceptional profitability, and a solid balance sheet, making it a standout pick for long-term investors.
SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ResMed (NYSE:RMD) and the best and worst performers in the patient monitoring industry.
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion.
The best of these businesses balance profitability with reinvestment, setting themselves up for long-term success.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Monday. Stay informed about the latest market trends.
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 7.9% year on year to $1.29 billion. Its non-GAAP profit of $2.37 per share was in line with analysts’ consensus estimates.
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade tensions boosts risk sentiment.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session.
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 7.9% year on year to $1.29 billion. Its non-GAAP profit of $2.37 per share was in line with analysts’ consensus estimates.
Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration helped lift investor confidence.
